Top

Osteoporosis International

Published in:

01-10-2011 | Original Article

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

Authors: J. Iwamoto, K. Makita, Y. Sato, T. Takeda, H. Matsumoto

Published in: Osteoporosis International | Issue 10/2011

Abstract

Summary

A randomized controlled trial was performed to compare the short-term effects of alendronate (ALN) and ECT on pain and quality of life (QOL) in postmenopausal women with osteoporosis. Back pain and QOL [Short-Form Health Survey (SF-8)] significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. These results suggested that ALN reduced back pain and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.

Introduction

Intramuscular ECT is known to reduce pain via the central nervous system. A multicenter randomized controlled trial was performed to compare the short-term effects of ALN and ECT on pain and QOL in postmenopausal women with osteoporosis.

Methods

One hundred and 94 postmenopausal osteoporotic women with back pain (mean age 79.8 years, range 60–96 years) were randomly divided into two groups: the ALN group (35 mg weekly) and the ECT group (intramuscular 20 units a week). The duration of the study was 6 months. The trial was completed in 97 (100%) women of the ALN group and 96 (99.0%) women of the ECT group. Urinary levels of cross-linked N-terminal telopeptide of type I collagen (NTX), serum alkaline phosphatase (ALP), face scale score (FSS, back pain), and SF-8 (QOL) were monitored.

Results

Urinary NTX levels significantly decreased at 3 months in the ALN group, but not in the ECT group. Serum ALP levels significantly decreased at 6 months in the both groups, with a greater reduction in the ALN group. The FSS and SF-8 significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group.

Conclusions

ALN suppressed bone turnover, reduced back pain, and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.

Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanism of action of bisphosphonate. Bone 24(5 Suppl):73S–79SPubMedCrossRef

Iwamoto J, Takeda T, Sato Y (2006) Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 22:919–928PubMedCrossRef

Iwamoto J, Takeda T, Sato Y (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis—usefulness of alendronate and risedronate. Expert Opin Pharmacother 8:2743–2756PubMedCrossRef

Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483–489PubMed

Morikawa T, Munekata E, Sakakibara S, Noda T, Otani M (1976) Synthesis of eel-calcitonin and (asu1, 7)-eel-calcitonin: contribution of the disulfide bond to the hormonal activity. Experientia 32:1104–1106PubMedCrossRef

Otani M, Kitazawa S, Yamaguchi H, Meguro T, Orimo H (1978) Biological activity of (asu1, 7)-eel-calcitonin. Clin Med 20:2217–2222 (in Japanese)

Orimo H (1990) The development of a novel therapy for bone disease, the discovery of elcatonin. In: Christiansen C, Overgard K (eds) Osteoporosis 1990. Handelstrykkeriet, Aalborg, pp 2091–2095

Yamamoto I, Morita R, Fukunaga M, Dokoh S, Shigeno C, Torizuka K, Noda T (1981) Adenylate cyclase activation and competitive binding with renal tissue using synthetic eel calcitonin analog and its fragments. Endocrinology 108:698–702PubMedCrossRef

Asahi-Kasei (2003) Outline of the results of a clinical trial of intramuscular elcatonin 20 S. http://www.asahi-kasei.co.jp/asahi/jp/news/2003/pdf/me030606 (in Japanese)

10.

Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23:167–173PubMedCrossRef

11.

Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture intervention trial research group. Arch Intern Med 160:77–85

12.

Miller PD, Shergy WJ, Body JJ, Chen P, Rohe ME, Krege JH (2005) Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32:1556–1562PubMed

13.

Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M (2003) Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 8:532–537PubMedCrossRef

14.

Iwamoto J, Takeda T, Ichimura S, Uzawa M (2003) Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. Keio J Med 52:230–235PubMedCrossRef

15.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 23:383–389PubMedCrossRef

16.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging Clin Exp Res 17:157–163PubMed

17.

Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K (2010) Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 17:209–213

18.

Kawate H, Ohnaka K, Adachi M, Kono S, Ikematsu H, Matsuo H, Higuchi K, Takayama T, Takayanagi R (2010) Alendronate improves QOL of postmenopausal women with osteoporosis. Clin Interv Aging 5:123–131PubMedCrossRef

19.

Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150CrossRef

20.

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRef

21.

Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388PubMedCrossRef

22.

Orimo H, Morii H, Inoue T, Yamamoto K, Minaguchi H, Ishii Y, Morita K, Fujimaki E, Watanabe R, Harada S, Honjo H, Fujita T (1996) Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73–78CrossRef

23.

Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29:906–909PubMedCrossRef

24.

Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2004) Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 23:97–104CrossRef

25.

Shibata K, Takeda M, Ito A, Sagai H (1998) Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol Biochem Behav 60:371–376PubMedCrossRef

26.

Martin MI, Goicoechea C, Ormazabal MJ, Lopez F, Alfaro MJ (1995) Analgesic effect of two calcitonins and in vitro interaction with opioids. Gen Pharmacol 26:641–647PubMed

27.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Med J 45:676–682PubMed

28.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J 46:750–758PubMedCrossRef

29.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab 23:238–242PubMedCrossRef

30.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2007) Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol 26:161–167PubMedCrossRef

31.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2008) Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J 49:119–128PubMedCrossRef

32.

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H (2002) The efficacy of alendronate in reducing the risk of vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp 63:606–620CrossRef

33.

Agarwala S, Sule A, Pai BU, Joshi VR (2002) Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 41:346–347CrossRef

34.

Gangji V, Appelboom T (1999) Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 18:266–267PubMedCrossRef

35.

Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949–2955PubMedCrossRef

36.

Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529–533PubMedCrossRef

37.

Hortobagyi GN, Terhiault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791PubMedCrossRef

38.

Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998) Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032–1038PubMedCrossRef

39.

Brown MF, Hukkanen MV, McCarthy ID, Redfern DR, Batten JJ, Crock HV, Hughes SP, Polak JM (1997) Sensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. J Bone Joint Surg Br 79:147–153PubMedCrossRef

40.

Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St Germain D, Ronsaville D, Sonbolian N, Torvik S, Calis KA, Phillips TM, Cizza G, Premenopausal, Osteoporosis, Women, Alendronate, Depression (P.O.W.E.R.) Study Group (2006) Quality of life and pain in premenopausal women with major depressive disorder: the POWER study. Health Qual Life Outcomes 4:2PubMedCrossRef

41.

Ohtori S, Inoue G, Koshi T, Ito T, Watanabe T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K (2007) Sensory innervation of lumbar vertebral bodies in rats. Spine 32:1498–1502, Philadelphia, PAPubMedCrossRef

42.

Ohtori S, Inoue G, Koshi T, Ito T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K (2007) Characteristics of sensory dorsal root ganglia neurons innervating the lumbar vertebral body in rats. J Pain 8:483–488PubMedCrossRef

43.

Bianchi M, Franchi S, Ferrario P, Sotgiu ML, Sacerdote P (2008) Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. Eur J Pain 12:284–292PubMedCrossRef

44.

Orita S, Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, Eguchi Y, Kamoda H, Arai G, Ishikawa T, Miyagi M, Ochiai N, Kishida S, Takaso M, Aoki Y, Toyone T, Takahashi K (2010) The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation. Spine 35:1974–1982PubMedCrossRef

45.

Wagner R, Myers RR (1996) Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 73:625–629PubMedCrossRef

46.

Wagner R, Myers RR (1996) Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. NeuroReport 7:2897–2901PubMedCrossRef

47.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437PubMedCrossRef

48.

Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553PubMedCrossRef

Title: Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis
Authors: J. Iwamoto
K. Makita
Y. Sato
T. Takeda
H. Matsumoto
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1495-8

At a glance: The STEP trials

Springer Medicine

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2011

Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis

Partial adherence: a new perspective on health economic assessment in osteoporosis

Erratum to: Effects of calcium-fortified ice cream on markers of bone health

Hip fractures in a city in Northern Norway over 15 years: time trends, seasonal variation and mortality

Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts

Effects of calcium-fortified ice cream on markers of bone health